English
简体中文
Total: £ 56.28
Published Date: 2025-11-05 | Pages: 116 | Tables: 107 | Medical Care
The global market for Antibody Drug Conjugates Contract Manufacturing was estimated to be worth US$ 3863 million in 2024 and is forecast to a readjusted size of US$ 12780 million by 2031 with a CAGR of 18.9% during the forecast period 2025-2031.
ADCs are mainly composed of three parts: antibodies, linkers, and cytotoxic loads. They are a type of bioactive cytotoxic drugs that are linked to monoclonal antibodies through chemical bonds and use monoclonal antibodies as carriers to target and transport cytotoxic drugs to target cells. Complex that works. The design concept of ADC was first proposed by Paul Ehrlich in the early 20th century. In 2000, the U.S. Food and Drug Administration (FDA) approved the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), for the treatment of acute myeloid myelopathy in adults. Leukemic cell lines, marking the beginning of the era of ADC-targeted cancer therapy.
Key global companies of Antibody Drug Conjugates Contract Manufacturing (ADC) include Lonza, Merck, Recipharm, Thermo Fisher, AbbVie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions and Curia. The top three players are Lonza, Merck and Recipharm, which together account for about 50% of the global market share. The largest player is Lonza Group. From the production side, the global players are mainly concentrated in North America and Europe. North America accounts for about 35% of the global market share. In terms of type, IgG1 dominates the global antibody drug conjugate contract manufacturing market. In terms of application, solid tumor applications account for more than half of the market.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugates Contract Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Antibody Drug Conjugates Contract Manufacturing by region & country, by Type, and by Application.
The Antibody Drug Conjugates Contract Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugates Contract Manufacturing.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antibody Drug Conjugates Contract Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Antibody Drug Conjugates Contract Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Antibody Drug Conjugates Contract Manufacturing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Antibody Drug Conjugates Contract Manufacturing Product Introduction
1.2 Global Antibody Drug Conjugates Contract Manufacturing Market Size Forecast (2020-2031)
1.3 Antibody Drug Conjugates Contract Manufacturing Market Trends & Drivers
1.3.1 Antibody Drug Conjugates Contract Manufacturing Industry Trends
1.3.2 Antibody Drug Conjugates Contract Manufacturing Market Drivers & Opportunity
1.3.3 Antibody Drug Conjugates Contract Manufacturing Market Challenges
1.3.4 Antibody Drug Conjugates Contract Manufacturing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antibody Drug Conjugates Contract Manufacturing Players Revenue Ranking (2024)
2.2 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Company (2020-2025)
2.3 Key Companies Antibody Drug Conjugates Contract Manufacturing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Antibody Drug Conjugates Contract Manufacturing Product Offered
2.5 Key Companies Time to Begin Mass Production of Antibody Drug Conjugates Contract Manufacturing
2.6 Antibody Drug Conjugates Contract Manufacturing Market Competitive Analysis
2.6.1 Antibody Drug Conjugates Contract Manufacturing Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Antibody Drug Conjugates Contract Manufacturing Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugates Contract Manufacturing as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 IgG1
3.1.2 IgG4
3.2 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Type
3.2.1 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Antibody Drug Conjugates Contract Manufacturing Sales Value, by Type (2020-2031)
3.2.3 Global Antibody Drug Conjugates Contract Manufacturing Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Solid Tumors
4.1.2 Hematological Malignancies
4.2 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Application
4.2.1 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Antibody Drug Conjugates Contract Manufacturing Sales Value, by Application (2020-2031)
4.2.3 Global Antibody Drug Conjugates Contract Manufacturing Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region
5.1.1 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (2020-2025)
5.1.3 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (2026-2031)
5.1.4 Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
5.2.2 North America Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
5.3.2 Europe Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
5.4.2 Asia Pacific Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
5.5.2 South America Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
5.6.2 Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antibody Drug Conjugates Contract Manufacturing Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.3 United States
6.3.1 United States Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.3.2 United States Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.4.2 Europe Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.5.2 China Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.5.3 China Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.6.2 Japan Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.7.2 South Korea Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.8.2 Southeast Asia Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020-2031
6.9.2 India Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
6.9.3 India Antibody Drug Conjugates Contract Manufacturing Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Lonza Group
7.1.1 Lonza Group Profile
7.1.2 Lonza Group Main Business
7.1.3 Lonza Group Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.1.4 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.1.5 Lonza Group Recent Developments
7.2 Merck KGaA
7.2.1 Merck KGaA Profile
7.2.2 Merck KGaA Main Business
7.2.3 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.2.4 Merck KGaA Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.2.5 Merck KGaA Recent Developments
7.3 Recipharm
7.3.1 Recipharm Profile
7.3.2 Recipharm Main Business
7.3.3 Recipharm Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.3.4 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.3.5 Recipharm Recent Developments
7.4 Thermo Fisher Scientific
7.4.1 Thermo Fisher Scientific Profile
7.4.2 Thermo Fisher Scientific Main Business
7.4.3 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.4.4 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.4.5 Thermo Fisher Scientific Recent Developments
7.5 Abbvie
7.5.1 Abbvie Profile
7.5.2 Abbvie Main Business
7.5.3 Abbvie Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.5.4 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.5.5 Abbvie Recent Developments
7.6 Piramal Pharma Solutions
7.6.1 Piramal Pharma Solutions Profile
7.6.2 Piramal Pharma Solutions Main Business
7.6.3 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.6.4 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.6.5 Piramal Pharma Solutions Recent Developments
7.7 Catalent
7.7.1 Catalent Profile
7.7.2 Catalent Main Business
7.7.3 Catalent Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.7.4 Catalent Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.7.5 Catalent Recent Developments
7.8 Sterling Pharma Solutions
7.8.1 Sterling Pharma Solutions Profile
7.8.2 Sterling Pharma Solutions Main Business
7.8.3 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.8.4 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.8.5 Sterling Pharma Solutions Recent Developments
7.9 Curia
7.9.1 Curia Profile
7.9.2 Curia Main Business
7.9.3 Curia Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.9.4 Curia Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.9.5 Curia Recent Developments
7.10 Novasep
7.10.1 Novasep Profile
7.10.2 Novasep Main Business
7.10.3 Novasep Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.10.4 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.10.5 Novasep Recent Developments
7.11 Ajinomoto Bio-Pharma Services
7.11.1 Ajinomoto Bio-Pharma Services Profile
7.11.2 Ajinomoto Bio-Pharma Services Main Business
7.11.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.11.4 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.11.5 Ajinomoto Bio-Pharma Services Recent Developments
7.12 BSP Pharmaceuticals
7.12.1 BSP Pharmaceuticals Profile
7.12.2 BSP Pharmaceuticals Main Business
7.12.3 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.12.4 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.12.5 BSP Pharmaceuticals Recent Developments
7.13 Cerbios-Pharma
7.13.1 Cerbios-Pharma Profile
7.13.2 Cerbios-Pharma Main Business
7.13.3 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.13.4 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.13.5 Cerbios-Pharma Recent Developments
7.14 Goodwin Biotechnology
7.14.1 Goodwin Biotechnology Profile
7.14.2 Goodwin Biotechnology Main Business
7.14.3 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
7.14.4 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue (US$ Million) & (2020-2025)
7.14.5 Goodwin Biotechnology Recent Developments
8 Industry Chain Analysis
8.1 Antibody Drug Conjugates Contract Manufacturing Industrial Chain
8.2 Antibody Drug Conjugates Contract Manufacturing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antibody Drug Conjugates Contract Manufacturing Sales Model
8.5.2 Sales Channel
8.5.3 Antibody Drug Conjugates Contract Manufacturing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Antibody Drug Conjugates Contract Manufacturing Market Trends
Table 2. Antibody Drug Conjugates Contract Manufacturing Market Drivers & Opportunity
Table 3. Antibody Drug Conjugates Contract Manufacturing Market Challenges
Table 4. Antibody Drug Conjugates Contract Manufacturing Market Restraints
Table 5. Global Antibody Drug Conjugates Contract Manufacturing Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share by Company (2020-2025)
Table 7. Key Companies Antibody Drug Conjugates Contract Manufacturing Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Antibody Drug Conjugates Contract Manufacturing Product Type
Table 9. Key Companies Time to Begin Mass Production of Antibody Drug Conjugates Contract Manufacturing
Table 10. Global Antibody Drug Conjugates Contract Manufacturing Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugates Contract Manufacturing as of 2024)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 14. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (2020-2025) & (US$ Million)
Table 15. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (2026-2031) & (US$ Million)
Table 16. Global Antibody Drug Conjugates Contract Manufacturing Sales Market Share in Value by Type (2020-2025)
Table 17. Global Antibody Drug Conjugates Contract Manufacturing Sales Market Share in Value by Type (2026-2031)
Table 18. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 19. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (2020-2025) & (US$ Million)
Table 20. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (2026-2031) & (US$ Million)
Table 21. Global Antibody Drug Conjugates Contract Manufacturing Sales Market Share in Value by Application (2020-2025)
Table 22. Global Antibody Drug Conjugates Contract Manufacturing Sales Market Share in Value by Application (2026-2031)
Table 23. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 24. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (2020-2025) & (US$ Million)
Table 25. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (2026-2031) & (US$ Million)
Table 26. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (2020-2025) & (%)
Table 27. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (2026-2031) & (%)
Table 28. Key Countries/Regions Antibody Drug Conjugates Contract Manufacturing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 29. Key Countries/Regions Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2025) & (US$ Million)
Table 30. Key Countries/Regions Antibody Drug Conjugates Contract Manufacturing Sales Value, (2026-2031) & (US$ Million)
Table 31. Lonza Group Basic Information List
Table 32. Lonza Group Description and Business Overview
Table 33. Lonza Group Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 34. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Lonza Group (2020-2025)
Table 35. Lonza Group Recent Developments
Table 36. Merck KGaA Basic Information List
Table 37. Merck KGaA Description and Business Overview
Table 38. Merck KGaA Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 39. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Merck KGaA (2020-2025)
Table 40. Merck KGaA Recent Developments
Table 41. Recipharm Basic Information List
Table 42. Recipharm Description and Business Overview
Table 43. Recipharm Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 44. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Recipharm (2020-2025)
Table 45. Recipharm Recent Developments
Table 46. Thermo Fisher Scientific Basic Information List
Table 47. Thermo Fisher Scientific Description and Business Overview
Table 48. Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 49. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Thermo Fisher Scientific (2020-2025)
Table 50. Thermo Fisher Scientific Recent Developments
Table 51. Abbvie Basic Information List
Table 52. Abbvie Description and Business Overview
Table 53. Abbvie Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 54. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Abbvie (2020-2025)
Table 55. Abbvie Recent Developments
Table 56. Piramal Pharma Solutions Basic Information List
Table 57. Piramal Pharma Solutions Description and Business Overview
Table 58. Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 59. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Piramal Pharma Solutions (2020-2025)
Table 60. Piramal Pharma Solutions Recent Developments
Table 61. Catalent Basic Information List
Table 62. Catalent Description and Business Overview
Table 63. Catalent Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 64. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Catalent (2020-2025)
Table 65. Catalent Recent Developments
Table 66. Sterling Pharma Solutions Basic Information List
Table 67. Sterling Pharma Solutions Description and Business Overview
Table 68. Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 69. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Sterling Pharma Solutions (2020-2025)
Table 70. Sterling Pharma Solutions Recent Developments
Table 71. Curia Basic Information List
Table 72. Curia Description and Business Overview
Table 73. Curia Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 74. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Curia (2020-2025)
Table 75. Curia Recent Developments
Table 76. Novasep Basic Information List
Table 77. Novasep Description and Business Overview
Table 78. Novasep Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 79. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Novasep (2020-2025)
Table 80. Novasep Recent Developments
Table 81. Ajinomoto Bio-Pharma Services Basic Information List
Table 82. Ajinomoto Bio-Pharma Services Description and Business Overview
Table 83. Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 84. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Ajinomoto Bio-Pharma Services (2020-2025)
Table 85. Ajinomoto Bio-Pharma Services Recent Developments
Table 86. BSP Pharmaceuticals Basic Information List
Table 87. BSP Pharmaceuticals Description and Business Overview
Table 88. BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 89. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of BSP Pharmaceuticals (2020-2025)
Table 90. BSP Pharmaceuticals Recent Developments
Table 91. Cerbios-Pharma Basic Information List
Table 92. Cerbios-Pharma Description and Business Overview
Table 93. Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 94. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Cerbios-Pharma (2020-2025)
Table 95. Cerbios-Pharma Recent Developments
Table 96. Goodwin Biotechnology Basic Information List
Table 97. Goodwin Biotechnology Description and Business Overview
Table 98. Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Products, Services and Solutions
Table 99. Revenue (US$ Million) in Antibody Drug Conjugates Contract Manufacturing Business of Goodwin Biotechnology (2020-2025)
Table 100. Goodwin Biotechnology Recent Developments
Table 101. Key Raw Materials Lists
Table 102. Raw Materials Key Suppliers Lists
Table 103. Antibody Drug Conjugates Contract Manufacturing Downstream Customers
Table 104. Antibody Drug Conjugates Contract Manufacturing Distributors List
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Antibody Drug Conjugates Contract Manufacturing Product Picture
Figure 2. Global Antibody Drug Conjugates Contract Manufacturing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Antibody Drug Conjugates Contract Manufacturing Sales Value (2020-2031) & (US$ Million)
Figure 4. Antibody Drug Conjugates Contract Manufacturing Report Years Considered
Figure 5. Global Antibody Drug Conjugates Contract Manufacturing Players Revenue Ranking (2024) & (US$ Million)
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Antibody Drug Conjugates Contract Manufacturing Revenue in 2024
Figure 7. Antibody Drug Conjugates Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 8. IgG1 Picture
Figure 9. IgG4 Picture
Figure 10. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 11. Global Antibody Drug Conjugates Contract Manufacturing Sales Value Market Share by Type, 2024 & 2031
Figure 12. Product Picture of Solid Tumors
Figure 13. Product Picture of Hematological Malignancies
Figure 14. Global Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 15. Global Antibody Drug Conjugates Contract Manufacturing Sales Value Market Share by Application, 2024 & 2031
Figure 16. North America Antibody Drug Conjugates Contract Manufacturing Sales Value (2020-2031) & (US$ Million)
Figure 17. North America Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
Figure 18. Europe Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 19. Europe Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
Figure 20. Asia Pacific Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 21. Asia Pacific Antibody Drug Conjugates Contract Manufacturing Sales Value by Region (%), 2024 VS 2031
Figure 22. South America Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 23. South America Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
Figure 24. Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 25. Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Sales Value by Country (%), 2024 VS 2031
Figure 26. Key Countries/Regions Antibody Drug Conjugates Contract Manufacturing Sales Value (%), (2020-2031)
Figure 27. United States Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 28. United States Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 29. United States Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 30. Europe Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 31. Europe Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 32. Europe Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 33. China Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 34. China Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 35. China Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 36. Japan Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 37. Japan Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 38. Japan Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 39. South Korea Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 40. South Korea Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 41. South Korea Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 42. Southeast Asia Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 43. Southeast Asia Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 44. Southeast Asia Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 45. India Antibody Drug Conjugates Contract Manufacturing Sales Value, (2020-2031) & (US$ Million)
Figure 46. India Antibody Drug Conjugates Contract Manufacturing Sales Value by Type (%), 2024 VS 2031
Figure 47. India Antibody Drug Conjugates Contract Manufacturing Sales Value by Application (%), 2024 VS 2031
Figure 48. Antibody Drug Conjugates Contract Manufacturing Industrial Chain
Figure 49. Antibody Drug Conjugates Contract Manufacturing Manufacturing Cost Structure
Figure 50. Channels of Distribution (Direct Sales, and Distribution)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
